Ding Chen1, Meng-Qi Song2, Yan-Jun Liu3, Yin-Kai Xue4, Ping Cheng5, Hai Zheng6, Li-Bo Chen7. 1. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: dchenjx@gmail.com. 2. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: smengqi@126.com. 3. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: yan122223@163.com. 4. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: renkai8@yeah.net. 5. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: pingc688@126.com. 6. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: zhenghai999@126.com. 7. Department of Emergency, Wuhan Union Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology, PR China. Electronic address: Li-BoChen@outlook.com.
Abstract
BACKGROUND: Vascular hyporeactivity in severe hemorrhagic shock could induce refractory hypotension and is an important cause of death. The global acute inflammatory response induced in shock triggers the over-expression of reactive oxygen species, NO, ET1 and TNF-α, which play essential roles in the pathology of vascular hyporeactivity. This leads to a hypothesis that inhibition of the complement system, the mediator of the inflammatory cascade, might be a promising therapeutic exploration for vascular hyporeactivity. METHODS: We use cobra venom factor (CVF) and the soluble form of CR1 (sCR1) which deplete or inhibit complement C3 respectively to examine its role in vascular hyporeactivity in a conscious hemorrhagic shock rat model. RESULTS: We first confirmed the over-activation of C3 during shock and the down-regulation effects of CVF and sCR1 on C3. Then, both CVF and sCR1 could significantly mitigate the over-expression of serum NO, ET-1, TNF-α and reactive oxygen species. Finally, the vascular reactivity of superior mesenteric arteries (SMA) was examined in vitro, which confirmed the massive reduction of vascular reactivity in shock, which was significantly rescued by both CVF and sCR1. CONCLUSIONS: Inhibition of C3 might improve the reactivity of SMA to norepinephrine during hemorrhagic shock possibly through the downregulation of NO, ET1, TNF-α and reactive oxygen radicals.
BACKGROUND: Vascular hyporeactivity in severe hemorrhagic shock could induce refractory hypotension and is an important cause of death. The global acute inflammatory response induced in shock triggers the over-expression of reactive oxygen species, NO, ET1 and TNF-α, which play essential roles in the pathology of vascular hyporeactivity. This leads to a hypothesis that inhibition of the complement system, the mediator of the inflammatory cascade, might be a promising therapeutic exploration for vascular hyporeactivity. METHODS: We use cobra venom factor (CVF) and the soluble form of CR1 (sCR1) which deplete or inhibit complement C3 respectively to examine its role in vascular hyporeactivity in a conscious hemorrhagic shockrat model. RESULTS: We first confirmed the over-activation of C3 during shock and the down-regulation effects of CVF and sCR1 on C3. Then, both CVF and sCR1 could significantly mitigate the over-expression of serum NO, ET-1, TNF-α and reactive oxygen species. Finally, the vascular reactivity of superior mesenteric arteries (SMA) was examined in vitro, which confirmed the massive reduction of vascular reactivity in shock, which was significantly rescued by both CVF and sCR1. CONCLUSIONS: Inhibition of C3 might improve the reactivity of SMA to norepinephrine during hemorrhagic shock possibly through the downregulation of NO, ET1, TNF-α and reactive oxygen radicals.
Authors: Martijn van Griensven; Daniel Ricklin; Stephanie Denk; Rebecca Halbgebauer; Christian K Braun; Anke Schultze; Felix Hönes; Sofia Koutsogiannaki; Alexandra Primikyri; Edimara Reis; David Messerer; Sebastian Hafner; Peter Radermacher; Ali-Reza Biglarnia; Ranillo R G Resuello; Joel V Tuplano; Benjamin Mayer; Kristina Nilsson; Bo Nilsson; John D Lambris; Markus Huber-Lang Journal: Shock Date: 2019-01 Impact factor: 3.454
Authors: Jean F Regal; Jenna M Lund; Cameron R Wing; Kate M Root; Luke McCutcheon; Lynne T Bemis; Jeffrey S Gilbert; Sherry D Fleming Journal: Mol Immunol Date: 2019-07-18 Impact factor: 4.407
Authors: Rebecca Halbgebauer; Ebru Karasu; Christian K Braun; Annette Palmer; Sonja Braumüller; Anke Schultze; Fabian Schäfer; Sarah Bückle; Alica Eigner; Ulrich Wachter; Peter Radermacher; Ranillo R G Resuello; Joel V Tuplano; Kristina Nilsson Ekdahl; Bo Nilsson; Milena Armacki; Alexander Kleger; Thomas Seufferlein; Miriam Kalbitz; Florian Gebhard; John D Lambris; Martijn van Griensven; Markus Huber-Lang Journal: Front Immunol Date: 2020-08-26 Impact factor: 7.561